Pfizer (PFE) vs Sanofi (SNY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pfizer (PFE) has outperformed Sanofi (SNY) over the past year, gaining 6.6% versus a loss of 17.6%. Over five years, SNY leads with a -17.6% price change compared with -32.5% for PFE. Pfizer is the larger company by market cap ($158.56 billion vs $96.40 billion), about 1.6 times the size.
On valuation, Sanofi trades at a lower forward P/E (7.4x vs 9.6x for Pfizer). Sanofi offers the higher dividend yield (10.24% vs 6.18%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PFE | SNY |
|---|---|---|
| Share price | $27.82 | $40.23 |
| Market cap | $158.56B | $96.40B |
| 1-day change | -0.64% | +0.07% |
| YTD return | +12.45% | -16.98% |
| 1-year return | +6.59% | -17.56% |
| 5-year return | -32.51% | -17.65% |
| P/E ratio (TTM) | 36.61 | 21.17 |
| Forward P/E | 9.60 | 7.45 |
| EPS (TTM) | $0.76 | $1.90 |
| Dividend yield | 6.18% | 10.24% |
| Annual dividend | $1.72 | $4.12 |
| Revenue (latest FY) | $62.58B | — |
| Revenue growth (YoY) | -1.65% | — |
| Net income (latest FY) | $7.77B | — |
| Gross margin | 74.33% | — |
| Net margin | 12.42% | — |
| 52-week high | $29.21 | $52.68 |
| 52-week low | $23.62 | $39.18 |
| Distance from 52-week high | -4.76% | -23.63% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +3.92% | +33.26% |
| Average volume | 35.94M | 2.89M |
| Shares outstanding | 5.70B | 2.40B |
| Employees | 75,000 | 74,846 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PFE has outperformed SNY by 24.1 percentage points over the past year.
- Pfizer trades at a higher earnings multiple (36.6x vs 21.2x trailing P/E).
- Sanofi offers a meaningfully higher dividend yield (10.24% vs 6.18%).
About Pfizer
PFE stock →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 75,000 employees
About Sanofi
SNY stock →Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Health Care · Biotechnology: Pharmaceutical Preparations · 74,846 employees
PFE vs SNY FAQ
Which is bigger, Pfizer or Sanofi?
Pfizer (PFE) is larger, with a market capitalization of $158.56B compared with $96.40B for Sanofi (SNY).
Which stock has performed better over the past year, PFE or SNY?
PFE returned +6.59% over the past 12 months, compared with -17.56% for SNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PFE or SNY?
SNY has the lower trailing P/E at 21.2, versus 36.6 for PFE. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Pfizer or Sanofi?
Sanofi has the higher yield at 10.24%, compared with 6.18% for Pfizer.
Are Pfizer and Sanofi in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.